Threshold’s lung cancer study does not meet goal
Threshold Pharmaceuticals Inc said a mid-stage study of its experimental drug glufosfamide to treat small cell lung cancer did not meet the main goal of objective response rate and that it will stop further enrollment in the trial.
This entry was posted on Friday, October 12th, 2007 at 7:32 am and is filed under Research, Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.